We appreciate for a valuable comment by Araujo and Theobald. Numerous studies have been supported the prognostic role of comorbidity/performance indices in many cancer including urological malignancies such as prostate, bladder, and renal cell carcinoma ([@B1][@B2][@B3]).

We also concede that other comorbidity indices such as Charlson comorbidity index (CCI), Adult Comorbidity Evaluation-27 (ACE-27), Eastern Cooperative Oncology Group performance status (ECOG-PS), and Karnofsky performance status (KPS) are more appropriate for decision of chemotherapy eligibility and prediction of cancer related survival than American Society of Anesthesiologists physical status (ASA-PS) ([@B4]).

Previous frontier study by Berod et al. ([@B5]) showed the correlation between ASA classification and cancer-specific survival (CSS) after radical nephroureterectomy (RNU) in upper tract urothelial carcinoma (UTUC) patients. Without doubt, the aim of our study is not to evaluate the application of ASA-PS in decision on chemotherapy eligibility, but to explore the background of prognostic value of ASA-PS in UTUC patients after RNU.

Although no significant survival impact of ASA-PS score on overall survival (OS) or CSS in patients with localized UTUC was observed in subgroup analysis, high ASA-PS groups with locally advanced disease probably reflects a worse physical status directly related to the cancer itself as your comment ([@B6]).

Unfortunately, our multi-institutional data did not include any information about PS and we could not adequately adjust for PS. Further co-operated study is needed to clarify the relationship among ASA-PS and cancer related survival in UTUC patients after RNU.
